Pfizer Has Recalled Rescriptor 200 mg tablets

New York, NY (SafetyAlerts) - The Food and Drug Administration (FDA) said that Pfizer Inc. has recalled Rescriptor 200 mg tablets (delavirdine mesylate tablets).

This is the first public notice of this Class lI recall issued by the FDA.

PRODUCT
Rescriptor 200 mg tablets (delavirdine mesylate tablets), NDC 0009-7576-01, Bottles of 180 tablets, Recall # D-041-2.

CODE
Lot no. 17DSJ Exp. date 11/01.

RECALLING FIRM/MANUFACTURER
Recalling Firm:
Pfizer Inc., New York, NY, by letter on 10/26/01.

Manufacturer:
Pharmacai & UpJohn Barceloneta, Puerto Rico. Firm initiated recall is ongoing.

REASON
Lowered therapeutic effectiveness.

VOLUME OF PRODUCT IN COMMERCE
1,949 bottles.

DISTRIBUTION
Nationwide.